48 results
8-K
EX-10.1
DMKPQ
DMK Pharmaceuticals Corp
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor
DEFM14A
DMKPQ
DMK Pharmaceuticals Corp
13 Apr 23
Proxy related to merger
4:52pm
will not be required to incur significant costs to comply with environmental and health and safety regulations in the future. Our research and development … , treated, otherwise managed or disposed. The costs of complying with, or other impact of, current or future environmental, health and safety
DEFA14A
EX-10.1
DMKPQ
DMK Pharmaceuticals Corp
6 Jul 22
Additional proxy soliciting materials
6:04am
, occupational health and safety, product quality and safety and employment and labor matters, except in each case as disclosed in the SEC Reports
8-K
EX-10.1
co19fqdyzb5xb
6 Jul 22
Entry into a Material Definitive Agreement
6:04am
8-K
EX-14.1
eslkzt h5
18 Feb 22
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:43pm
8-K
EX-10.1
dj299rrt5
21 Feb 20
Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering
5:24pm
10-KT
wdv yajz61m
26 Mar 15
Annual report (with FYE transition)
12:00am
10-KT
EX-10.50
enzxyf8sf3ap654
26 Mar 15
Annual report (with FYE transition)
12:00am
8-K
EX-1.1
69x002ba f2hod
17 Dec 13
Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000
12:00am